Melioidosis: A clinical model for gram-negative sepsis

Journal of Medical Microbiology

Volumn 50, Issue 8, 2001, Pages 657-658

  Simpson, A J H ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; RECOMBINANT PROTEIN;

BURKHOLDERIA PSEUDOMALLEI; DISEASE MODEL; EDITORIAL; GRAM NEGATIVE SEPSIS; MELIOIDOSIS; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RECURRENCE RISK;

EID: 0034923214     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-50-8-657     Document Type: Editorial

References (21)

1. Efficacy and safety of recombinant human activated protein C for severe sepsis
2. Meningococcal disease as a model to evaluate novel anti-sepsis strategies
3. Meningococcemia as a model for testing the hypothesis of antisepsis therapies
4. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
5. Melioidosis and Pandora's Box in the Lao People's Democratic Republic
6. Melioidosis as an emerging global problem
7. Endemic melioidosis in tropical northern Australia: A 10-year prospective study and review of the literature
8. Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei
9. Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei
10. Melioidosis: A major cause of community-acquired septicemia in northeastern Thailand
11. Halving of mortality of severe melioidosis by ceftazidime
12. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis
13. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis
14. Comparison of imipenem and ceftazidime as therapy for severe melioidosis
15. Relapse in melioidosis: Incidence and risk factors
16. Elevated plasma concentrations of Interferon-γ (IFN-γ) and the IFN-γ-inducing cytokines Interleukin (IL)-I8, IL-12 and IL-I5 in severe melioidosis
17. The CXC chemokines gamma interferon (IFN-γ)-inducible protein 10 and monokine induced by IFN-γ are released during severe melioidosis
18. Prognostic value of cytokine concentrations (Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10) and clinical parameters in severe melioidosis
19. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to Gram-negative bacteria
20. Differential antibiotic-induced endotoxin release in severe melioidosis
21. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis